MAPK and mTOR pathway activation is associated with chemotherapy resistance and a poor prognosis in G3 advanced NENs

#4219

Introduction: Neuroendocrine neoplasms (NENs) comprise a broad spectrum of disease ranging from slowly progressive to highly aggressive carcinomas.

Aim(s): The aim of our study was to identify dysregulated biological pathways and their relevance in clinical outcomes.

Materials and methods: NGS were performed in blood (N= 34), tumor tissue (N= 57) or both (n=14) from 105 patients (58 NETs [13, 28 & 17 were G1/G2/G3] and 47 NECs) treated between 2020 and 2023. The association between relevant alterations and clinical features was assessed with χ2 or Fisher’s tests and Kaplan-Meier.

Conference:

Presenting Author: Catoya J

Authors: Catoya J, Anton-Pascual B, Farinea G, Modrego A, La Salvia A,

Keywords: NEN, mTOR/MAPK pathway, molecular profiling, platinum-based,